Holen Sie sich die Stockscreener-App
3.38
3.68%
0.12
Vorhandelsmarkt:
3.47
0.09
+2.66%
Schlusskurs vom Vortag:
$3.26
Offen:
$3.27
24-Stunden-Volumen:
1.12M
Relative Volume:
0.91
Marktkapitalisierung:
$216.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.95M
KGV:
-4.0238
EPS:
-0.84
Netto-Cashflow:
$-33.46M
1W Leistung:
+6.96%
1M Leistung:
+30.50%
6M Leistung:
-2.31%
1J Leistung:
-64.27%
1-Tages-Spanne:
$3.25
$3.53
1-Wochen-Bereich:
$3.12
$3.53
52-Wochen-Spanne:
$1.61
$9.97
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Firmenname
Larimar Therapeutics Inc
Sektor
Branche
Telefon
844-511-9056
Adresse
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Vergleichen Sie LRMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.38 | 202.33M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-29 | Eingeleitet | Truist | Buy |
| 2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-03 | Eingeleitet | Wedbush | Outperform |
| 2024-10-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-03 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-19 | Eingeleitet | Guggenheim | Buy |
| 2022-02-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-02-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten
What drives Larimar Therapeutics Inc. stock priceRapidly expanding wealth - jammulinksnews.com
Is Larimar Therapeutics Inc. a good long term investmentMarket-leading capital gains - jammulinksnews.com
What analysts say about Larimar Therapeutics Inc. stockFree Popular Stock Recommendations - jammulinksnews.com
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Is Larimar Therapeutics Inc. stock overhyped or has real potentialHigh Return Investment Tips - Newser
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance
5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com
Why Larimar Therapeutics Inc. stock attracts strong analyst attentionTop Analyst Picks - Newser
What makes Larimar Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN
Larimar Nears Data Readout For Nomlabofusp In Rare Inherited Disorder - RTTNews
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia - MarketScreener
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia | LRMR Stock News - GuruFocus
Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment - Nasdaq
Larimar Therapeutics Publishes Nonclinical Data Supporting - GlobeNewswire
First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval - Stock Titan
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000 Value Index - MarketScreener
Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN
Guggenheim Reiterates Buy Rating for Larimar Therapeutics (LRMR) - GuruFocus
Larimar Therapeutics’ (LRMR) Buy Rating Reaffirmed at Guggenheim - Defense World
Analyst Lowers Price Target for Larimar Therapeutics (LRMR) | LRMR Stock News - GuruFocus
Larimar Therapeutics (LRMR) Target Price Reduced by Wedbush Amid FDA Delay | LRMR Stock News - GuruFocus
Larimar Therapeutics (LRMR) Sees Buying Opportunity After Share Decline | LRMR Stock News - GuruFocus
Larimar Therapeutics Updates on Nomlabofusp Progress - TipRanks
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Regulatory Update Call on - GlobeNewswire
Millennium Management LLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus
Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com
Finanzdaten der Larimar Therapeutics Inc-Aktie (LRMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):